Drug Profile
Antisense-TAR gene therapy
Latest Information Update: 13 Nov 2003
Price :
$50
*
At a glance
- Originator Genetic Therapy; National Institutes of Health (USA)
- Class Antivirals; Gene therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 13 Nov 2003 Discontinued - Preclinical for HIV-1 infections in USA (unspecified route)
- 30 Jul 1998 No-Development-Reported for HIV-1 infections in USA (Unknown route)
- 06 Mar 1995 Preclinical development for HIV-1 infections in USA (Unknown route)